Reprogramming Imbalanced Macrophage Populations May Play A Key Role In Resolving Cancer And Various Inflammatory Disorders

Shai Novik, Executive Chairman of the Board at Enlivex Therapeutics, Ltd. (NASDAQ:ENLV), was a guest speaker at Benzinga’s All Access on June 17th, 2022. 

Enlivex Therapeutics is a clinical stage, macrophage reprogramming immunotherapy company developing Allocetra - an off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state.

Watch full interview here

Feature photo 

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.